For the Inventor, By the Inventor

Enter inventor name

Daejeon, South Korea

Tae Kyo Park

USPTO Granted Patents = 16 (Patent Applications = 2)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 10)

Average Co-Inventor Count = 11.5

ph-index = 5

Forward Citations = 68(Granted Patents)

Company Filing History:

Legochem Biosciences, Inc.

Legochem Bioscience Ltd.

The Green Cross Corporation

Neopharm Co., Ltd.

where one patent can have more than one assignee

Years Active: 2012-2021

Loading Chart...

Loading Chart...

Loading Chart...

16 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11065343 - Compound bearing beta-galactoside-introduced self-immolative linker (2021-07-20),

2. 10980890 - Compounds comprising self-immolative group (2021-04-20),

3. 10383949 - Compounds comprising self-immolative group (2019-08-20),

4. 9993568 - Compounds comprising self-immolative group (2018-06-12),

5. 9988372 - Crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition comprising same (2018-06-05),

6. 9919057 - Compounds comprising self-immolative group (2018-03-20),

7. 9630977 - Cephalosporin derivatives and pharmaceutical compositions thereof (2017-04-25),

8. 8846669 - Oxazolidinone derivative and medical composition containing same (2014-09-30),

9. 8809541 - Heterocyclic compound, and composition for treating inflammatory diseases using same (2014-08-19),

10. 8754210 - Method for preparing 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl) derivative and intermediate used therein (2014-06-17),

11. 8703939 - Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives (2014-04-22),

12. 8637667 - Method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives (2014-01-28),

13. 8329684 - Cephalosporin derivatives and pharmaceutical compositions thereof (2012-12-11),

14. 8288423 - FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof (2012-10-16),

15. 8242113 - Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof (2012-08-14),

Title: Tae Kyo Park: Innovator in Self-Immolative Linkers

Introduction

Tae Kyo Park is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of innovative compounds that utilize self-immolative linkers. With a total of 16 patents to his name, Park's work has the potential to impact various applications in drug delivery and targeted therapies.

Latest Patents

Among his latest patents is a compound bearing a beta-galactoside-introduced self-immolative linker. This invention relates to a compound that can form a glycosidic bond with proteins or ligands that have a specific affinity for desired targets. This allows for the selective release of active agents within target cells, enhancing the efficacy of therapeutic interventions. Another notable patent involves compounds comprising a self-immolative group, which can include proteins with substrate-specificity for targets and active agents with specific functions.

Career Highlights

Tae Kyo Park has worked with notable companies such as Legochem Biosciences, Inc. and Legochem Bioscience Ltd. His experience in these organizations has allowed him to further his research and development efforts in the field of biochemistry.

Collaborations

Park has collaborated with esteemed colleagues, including Sung Ho Woo and Yong Zu Kim. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Tae Kyo Park is a distinguished inventor whose work in self-immolative linkers and related compounds holds promise for future advancements in targeted drug delivery systems. His contributions to the field are noteworthy and continue to inspire innovation in biochemistry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…